Astec LifeSciences shareholders approved the company’s consolidated financial statements for the financial year ended March 31, 2026, during its 32nd Annual General Meeting (AGM) held on July 31, 2026. The meeting, conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM), also resulted in the re-appointment of Mr. Ashok V. Hiremath as a non-executive, non-independent director and the ratification of remuneration for the cost auditor for the upcoming fiscal year. Shareholders voted overwhelmingly in favor of all three resolutions, signaling strong alignment with management’s governance and financial reporting practices.

The meeting was chaired by Mr. Vishal Sharma, who welcomed shareholders and outlined procedural aspects. The Board of Directors, along with representatives from statutory auditors B S R & Co. LLP and secretarial auditors BNP & Associates, attended the proceedings. Shareholders were provided with remote e-voting facilities through National Securities Depository Limited (NSDL), which commenced on July 26, 2026, and concluded on July 31, 2026.

Voting Results

All three resolutions placed before the shareholders were passed with overwhelming support. Mr. Vikas R. Chomal, Practicing Company Secretary, served as the scrutinizer for the voting process.

Key Governance Actions

The primary ordinary business item involved the adoption of the audited standalone and consolidated financial statements for the financial year ended March 31, 2026, along with the reports of the Board of Directors and statutory auditors. This resolution received near-unanimous approval, with only 258 votes cast against it out of over 1.73 crore valid votes polled.

Under special business, shareholders ratified the remuneration of M/s. Tapan Gaitonde & Co., Cost Accountants, as the cost auditor for the financial year ending March 31, 2027. The remuneration package includes up to ₹1,50,000 per annum plus ₹15,000 towards XBRL compilation, along with applicable Goods & Service Tax (GST) and reimbursement of out-of-pocket expenses.

Additionally, Mr. Ashok V. Hiremath, who retires by rotation, was re-appointed as a director. He is a non-executive, non-independent director who has been associated with the company since its inception in 1994. The resolution to re-appoint him passed with 99.9962% support.

What the Numbers Show

The high level of shareholder engagement and support underscores confidence in the company’s governance structure. With over 77% of outstanding shares participating in the vote, the results reflect strong alignment between the promoter group, institutional investors, and public shareholders on key strategic and compliance matters. The minimal dissent across all resolutions indicates broad consensus on the financial reporting and leadership continuity.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE563J01010/2454c281-b041-4e79-abf2-0ac6835181dc.pdf

Astec LifeSciences Limited has scheduled its 32nd Annual General Meeting (AGM) for Friday, July 31, 2026, at 4:00 p.m. IST via Video Conferencing (VC) and Other Audio Visual Means (OAVM). The meeting will be held to transact business including the adoption of audited financial statements for the Financial Year 2025-26 and the ratification of the Cost Auditor's remuneration. The company has confirmed the completion of dispatch of the AGM notice and Annual Report to shareholders, with advertisements published in Business Standard and Mumbai Lakshadeep on July 9, 2026.

AGM Schedule and Key Dates

Shareholders should note the following key dates associated with the 32nd AGM:

The venue of the 32nd AGM shall be deemed to be the Registered Office of the Company at "Godrej One", 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai – 400 079, Maharashtra, India. E-voting facilities are being provided through the National Securities Depository Limited (NSDL) platform.

Agenda Items at the 32nd AGM

The following business items are proposed to be transacted at the 32nd AGM:

• Ordinary Business: Adoption of Audited Financial Statements (Standalone and Consolidated) for the Financial Year ended March 31, 2026, along with the Reports of the Board of Directors and Statutory Auditors.
• Ordinary Business: Re-appointment of Mr. Ashok V. Hiremath (DIN: 00349345), Non-Executive, Non-Independent Director, who retires by rotation and is eligible for re-appointment.
• Special Business: Ratification of remuneration of M/s. Tapan Gaitonde & Co., Cost Accountants, as Cost Auditor of the Company for the Financial Year ending March 31, 2027, at a remuneration of up to ₹1,50,000/- (Rupees One Lakh Fifty Thousand Only) per annum plus ₹15,000/- (Rupees Fifteen Thousand Only) towards XBRL compilation, plus applicable GST and reimbursement of out-of-pocket expenses.

IEPF and Unclaimed Dividend Notice

Shareholders are informed that the dividend amount for FY 2018-19 remaining unclaimed shall become due for transfer to the Investor Education and Protection Fund (IEPF) on Wednesday, August 26, 2026. Shareholders are requested to submit their claims preferably by Friday, August 7, 2026 to avoid transfer to IEPF. During FY 2025-26, 1,371 Equity Shares of Face Value of ₹10/- each, amounting to a nominal value of ₹13,710/-, were transferred to IEPF on account of unclaimed dividend for FY 2017-18.